Coherus BioSciences Inc. and Shanghai Junshi Biosciences Co. said they saw positive results from a study evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
The companies said the interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival compared with chemotherapy alone.
The study also met secondary endpoints of progression free survival assessed by the investigator and objective response rate assessed by a blinded independent review committee. There also was a longer duration of response, a higher disease control rate and higher one- and two-year survival rates for the toripalimab arm.
The safety profile of toripalimab was consistent with that observed in previously reported toripalimab clinical trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.